Metabolic CROs

Australian full-service CRO providing Phase 1–3 clinical trial management with expertise in biotech-focused programs. Known for the Australian Clinical Trial Notification (CTN) regulatory pathway advantage.

Adelaide-based Phase 1 clinical pharmacology unit conducting first-in-human, bioequivalence, and biosimilar studies. Operates a 150-bed facility at the Royal Adelaide Hospital campus.

London-based early phase CRO conducting Phase 1 healthy volunteer and patient studies. Operates a dedicated clinical pharmacology unit at the Cumberland Business Park with 100+ bed capacity.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

Sydney-based Phase 1 clinical pharmacology unit specializing in first-in-human studies, bioequivalence, and healthy volunteer trials. Part of the Novotech group.